The use of CRISPR/Tuba-seq indicated that KEAP1 inactivation considerably diminished the sensitivity of EGFR-driven lung adenocarcinoma to the EGFR inhibitor osimertinib in a TSGs pool (Foggetti et al., 2021). This evidence concerns the gene KEAP1 and lung adenocarcinoma.